Takeda Pharmaceutical Co. said Saturday its U.S.-based research and development center has received approval from the U.S. Food and Drug Administration for a new prescription insomnia medicine.

Rozerem, which is generically known as ramelteon and comes in 8-milligram tablets, is the first product of its kind that has shown no evidence of abuse and dependence and therefore has not been designated as a controlled substance by the Drug Enforcement Administration, the major pharmaceutical company said. Takeda said it will market the drug through its U.S. unit, without giving a timetable.

According to Takeda, ramelteon treats insomnia by specifically affecting the activity of neurons in an area of the brain involved in the sleep-wake process.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.